Radioactive oil injection may keep liver cancer at bay

NCT ID NCT00116454

Completed Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested whether a single injection of radioactive lipiodol (Lipiocis) into the liver artery could prevent hepatocellular carcinoma from coming back after surgery or ablation. The study enrolled 73 adults with cirrhosis and one or two liver tumors that had been successfully treated. The goal was to see if the treatment reduced tumor recurrence over two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radioactive lipiodol (Lipiocis)
What this could lead to: If it works, this could reduce the chance of liver cancer coming back after initial treatment, potentially improving long-term survival.
What could go wrong: This is a small, completed trial with only 73 participants, so results may not apply broadly. The treatment involves radiation and may cause liver toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, HEPATOCELLULAR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcoholic hepatitis hepatocellular carcinoma viral hepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, HEPATOCELLULAR HEPATITIS, VIRAL, HUMAN

Contacts and locations

Locations

Service d'Hépatologie Hôpital Saint Antoine

Paris, 75012, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.